What Emergency Preparedness Should Look Like

Most discussion of ibogaine safety is about screening, which happens before. This page is about the part that happens when screening has not been enough, and it is the part clinics describe least.

What the dangerous event actually is

Not a heart attack. Torsades de pointes, a specific ventricular arrhythmia that arises when the heart’s electrical recovery is prolonged.

Its behaviour explains everything that follows. The cardiology guidance notes that unlike ventricular fibrillation, which does not stop without defibrillation, torsades frequently terminates spontaneously. But in some cases it degenerates into ventricular fibrillation and causes sudden cardiac death.

So it is survivable, often, if somebody is there with the right equipment at the moment it happens. That conditional is the whole subject.

What actually works, and what does not

Here the ibogaine literature has a specific and uncomfortable answer.

A 2026 review in Addiction summarises the interventions applied in published hospitalised cases: anticonvulsants, isoproterenol and atropine for symptom management, and in several cases electrical cardioversion, a pacemaker, defibrillation and intubation. Its conclusion, and this is the sentence to carry:

aside from placing the pacemaker in some patients to reduce ventricular arrhythmias, most of the other clinical interventions treatments were not effective in resolving ventricular arrhythmias or Torsades des pointes.

The standard management from cardiology is consistent with that.

There is also a telling absence. The American Heart Association published a dedicated 2023 update on cardiac arrest from poisoning, covering benzodiazepines, beta-blockers, calcium channel antagonists, cocaine, cyanide, digoxin, local anaesthetics, opioids, organophosphates and sympathomimetics. Drugs that block the channel ibogaine blocks are not among its categories. There is no ibogaine-shaped entry in the guideline written for exactly this kind of emergency.

The two cases that show the difference

A man received a 200 mg test dose, a fraction of a treatment dose. One hour later he developed polymorphic ventricular tachycardia and cardiac arrest, and was defibrillated by the staff on site, regaining circulation after one shock. He then arrested twice more in the emergency department and a fourth time in intensive care, each requiring another shock. His QTc reached 636 milliseconds and normalised on day eight. He was discharged from intensive care on day nine.

He lived. His electrolytes had been normal, he had no structural heart disease, and nothing on a screening panel would have flagged him. What saved him was a defibrillator in the room and someone who could use it.

Against that: a 40-year-old man who used ibogaine for heroin withdrawal was found in asystole and progressed to brain death. And a man who bought powder online was found dead in a rented apartment where he was undergoing what he believed was a detoxification, between five and twelve hours after taking it.

The difference between those outcomes is not the drug. It is who was in the room.

How long the risk lasts, and why every protocol closes too early

This is the most useful comparison on the site and it comes from setting published documents against each other.

The risk window. Deaths in the fatality series occurred between 1.5 and 76 hours after ingestion. The metabolite noribogaine has a half-life of 28 to 49 hours. In one documented case the QT interval took seven days to normalise, in another eight, and in a third the prolongation persisted twelve days.

What protocols provide. The provider guidelines specify close supervision on a three-lead monitor for 12 to 24 hours. The Dutch hospital study ran 12-lead ECGs every half hour for 12 hours and continued to 24. The most-cited veteran study monitored the QTc visually for 12 to 16 hours.

No published protocol monitors for as long as the risk window it describes. Not the provider guidelines, not the academic studies.

The cardiology position on this is explicit. A 2015 review states that ibogaine should be permitted only under strict medical observation and continuous electrocardiographic monitoring for an extended period, which carefully takes noribogaine’s longevity in human plasma into account. And it notes that cardiac adverse events may occur several days, in some cases weeks, after a single dose.

What a facility needs, itemised

Each of these comes from a source, and each is a question with a factual answer.

• Continuous multi-lead cardiac monitoring, with a person watching it. Not a monitor in the room. A person, awake, at four in the morning.
• Intravenous magnesium sulfate immediately to hand, not in a locked cupboard elsewhere.
• A working external defibrillator, tested, with staff certified to use it.
• The ability to measure and correct potassium on the day, not from a result posted a week earlier.
• Intravenous access already established before dosing, because siting a line in someone convulsing is not a plan.

And the one that cannot be improvised:

The questions to ask

• Who is watching the monitor overnight, and what is their qualification?
• Is there a defibrillator, when was it last tested, and who is trained on it?
• Is intravenous magnesium in the room?
• How many minutes to a hospital that can manage a ventricular arrhythmia, and has anyone timed that drive at night?
• What happens on night two and night three, when every protocol has already stopped monitoring?
• Has anyone here ever had to use any of this?

How to evaluate a clinic sets those in the wider context, and ibogaine and the heart explains the mechanism this page exists to respond to.